Elliot Mark Frohman

Elliot Mark Frohman's AcademicInfluence.com Rankings

Elliot Mark Frohman

Medical

#3105

World Rank

#3560

Historical Rank

Neurology

#287

World Rank

#369

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Elliot Mark Frohman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Elliot Mark Frohman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Multiple sclerosis--the plaque and its pathogenesis. (2006) (1668)
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. (2006) (649)
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) (641)
Immune surveillance in multiple sclerosis patients treated with natalizumab (2006) (435)
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis (2010) (332)
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis (2011) (318)
Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. (2012) (313)
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis (2017) (310)
Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis (2017) (310)
Optical coherence tomography: a window into the mechanisms of multiple sclerosis (2008) (302)
Optical coherence tomography and disease subtype in multiple sclerosis (2007) (295)
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. (2011) (284)
Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four‐year study (2015) (272)
Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies (2009) (271)
Multiple sclerosis and the urologist. (1999) (266)
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. (2006) (263)
Ganglion cell loss in relation to visual disability in multiple sclerosis. (2012) (257)
Factors that influence adherence with disease-modifying therapy in MS (2009) (257)
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study (2012) (256)
The neuro-ophthalmology of multiple sclerosis (2005) (253)
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness (2011) (248)
Assessment: Vestibular testing techniques in adults and children (2000) (248)
Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria (2015) (234)
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis (2007) (234)
The induction of intercellular adhesion molecule 1 (ICAM-1) expression on human fetal astrocytes by interferon-λ, tumor necrosis factor α, lymphotoxin, and interleukin-1: relevance to intracerebral antigen presentation (1989) (233)
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study (2016) (231)
Assessment: Prevention of post–lumbar puncture headaches (2000) (228)
The thalamus and multiple sclerosis (2013) (210)
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. (2005) (207)
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. (2002) (202)
Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. (1997) (198)
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning (2013) (197)
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. (2012) (196)
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. (2009) (185)
Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. (2008) (183)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (176)
Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) (171)
Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for Neurodegeneration (2010) (160)
Thermoregulation in multiple sclerosis. (2010) (143)
Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. (1988) (134)
Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (2016) (132)
Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. (2008) (127)
Current and emerging therapies in multiple sclerosis: a systematic review (2012) (124)
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: A pilot study (2009) (119)
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? (2010) (117)
Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease (1991) (116)
Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. (2006) (115)
Extended interval dosing of natalizumab in multiple sclerosis (2016) (114)
Bladder, bowel, and sexual dysfunction in multiple sclerosis (2001) (110)
The role of optical coherence tomography in multiple sclerosis: Expert panel consensus (2007) (106)
Memory B cells from a subset of treatment‐naïve relapsing‐remitting multiple sclerosis patients elicit CD4+ T‐cell proliferation and IFN‐γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein (2010) (106)
Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success (2012) (103)
Reproducibility of high-resolution optical coherence tomography in multiple sclerosis (2010) (101)
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica (2013) (97)
Clinical practice. Transverse myelitis. (2010) (97)
Are astrocytes central players in the pathophysiology of multiple sclerosis? (2003) (96)
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2004) (96)
Transverse Myelitis (2012) (89)
Interferon-β specifically inhibits interferon-γ-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line (1991) (89)
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. (2006) (86)
Pearls & Oy-sters: The medial longitudinal fasciculus in ocular motor physiology (2008) (84)
Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management (2009) (83)
Reproducibility of optical coherence tomography in multiple sclerosis. (2008) (82)
Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes (1988) (81)
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. (2009) (81)
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis (2006) (80)
Uhthoff's phenomena in MS—clinical features and pathophysiology (2013) (78)
In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques (2012) (77)
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician (2008) (76)
Mycophenolate Mofetil in Multiple Sclerosis (2004) (76)
Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity (2010) (72)
Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. (2008) (69)
JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. (2014) (69)
Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients (2005) (69)
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. (2007) (68)
Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study (2019) (67)
Accuracy of clinical detection of INO in MS (2003) (67)
Retinal Ganglion Cell Layer Volumetric Assessment by Spectral-Domain Optical Coherence Tomography in Multiple Sclerosis: Application of a High-Precision Manual Estimation Technique (2011) (67)
Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. (2011) (66)
The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials (2011) (66)
The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. (2014) (64)
Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients (2008) (64)
Gap-overlap effects on latencies of saccades, vergence and combined vergence-saccades in humans (1995) (64)
[Transverse myelitis]. (2010) (63)
Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. (2008) (62)
Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection (2007) (60)
One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. (2011) (59)
Outer retinal changes following acute optic neuritis (2016) (59)
Characterization of retinal architecture in Parkinson's disease (2015) (59)
Acquired sexual paraphilia in patients with multiple sclerosis. (2002) (59)
Dynamic pupillometry as an autonomic testing tool (2013) (59)
Antibody-independent B cell effector functions in relapsing remitting Multiple Sclerosis: Clues to increased inflammatory and reduced regulatory B cell capacity (2012) (59)
Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques (2003) (58)
Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis (2008) (57)
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis (2009) (57)
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies (2021) (56)
Ocular neuromyotnia: Clinical features, physiological mechanisms, and response to therapy (1995) (56)
Multiple sclerosis. (2003) (55)
MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis.11Neurology 2001;57:762–768. (2001) (54)
Disease-modifying therapies modulate retinal atrophy in multiple sclerosis (2017) (54)
Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score (2002) (54)
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis (2000) (54)
Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS (2007) (52)
Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis (2015) (50)
Retinal damage and vision loss in African American multiple sclerosis patients (2015) (49)
Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells. (2014) (48)
Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (2012) (48)
MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis (2001) (48)
Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome. (2004) (47)
Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study (2018) (47)
Pharmacological Treatment of Early Multiple Sclerosis (2008) (46)
Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures (2019) (46)
Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management (2002) (46)
Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis (2018) (46)
More on JC viremia in natalizumab-treated patients with multiple sclerosis. (2013) (45)
Corticosteroids for multiple sclerosis: I. Application for treating exacerbations (2007) (45)
Optical coherence tomography as a potential readout in clinical trials (2010) (43)
PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease (2009) (43)
JC viremia in natalizumab-treated patients with multiple sclerosis. (2013) (42)
Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluation. (2006) (42)
Optical coherence tomography in multiple sclerosis (2006) (42)
Visual Pathway Axonal Loss in Benign Multiple Sclerosis: A Longitudinal Study (2012) (42)
Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis (2006) (41)
Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management (2004) (41)
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. (2005) (41)
Prion proteins: Physiological functions and role in neurological disorders (2008) (41)
Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice (2007) (40)
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. (2004) (37)
No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. (2011) (37)
Vestibular dysfunction in chronic inflammatory demyelinating Polyneuropathy (1996) (37)
Retinal measurements predict 10‐year disability in multiple sclerosis (2019) (37)
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy (2013) (37)
Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis. (2006) (37)
Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. (2014) (36)
Levetiracetam for phasic spasticity in multiple sclerosis. (2003) (35)
Surface ElectroMyoGraphy for (2003) (35)
Optic neuritis: A mechanistic view. (2011) (35)
A preliminary validation study of diffusion tensor imaging as a measure of functional brain injury. (2008) (35)
Vasoactive intestinal polypeptide inhibits the expression of the MHC class II antigens on astrocytes (1988) (34)
Cerebellar Control of Eye Movements (2017) (34)
CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics (2016) (33)
Re-evaluating the treatment of acute optic neuritis (2014) (33)
Hiding in plain sight: a closer look at posterior cortical atrophy (2014) (32)
Functional treatments in multiple sclerosis. (2011) (32)
A new measure of dysconjugacy in INO: the first-pass amplitude (2003) (30)
Immunologic mechanisms of multiple sclerosis. (2008) (30)
Ocular motor measures of cognitive dysfunction in multiple sclerosis I: inhibitory control (2015) (29)
20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought? (2015) (28)
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis (2010) (27)
Renal deterioration in multiple sclerosis patients with neurovesical dysfunction (2013) (26)
Aquatic training in MS: neurotherapeutic impact upon quality of life (2015) (26)
B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses (2016) (25)
Optimal Inter-Eye Difference Thresholds by OCT in MS: An International Study (2019) (25)
THE NEURO-OPHTHALMOLOGY OF MULTIPLE SCLEROSIS (2010) (25)
Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis (2017) (24)
Ocular contrapulsion in multiple sclerosis: clinical features and pathophysiological mechanisms (2001) (24)
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS (2012) (24)
Disease-modifying therapies for multiple sclerosis (2003) (24)
Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’1 attack (2020) (23)
Associations between retinal nerve fiber layer abnormalities and optic nerve examination (2010) (23)
Ocular motor signatures of cognitive dysfunction in multiple sclerosis (2015) (22)
Ocular motor measures of cognitive dysfunction in multiple sclerosis II: working memory (2015) (22)
Fatigue in multiple sclerosis: is the picture getting simpler or more complex? (2004) (22)
Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: [RETIRED] (2011) (21)
Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures. (2007) (21)
Autonomic Regulation of Neuroimmunological Responses: Implications for Multiple Sclerosis (2001) (21)
Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis (2011) (20)
Direct and consensual murine pupillary reflex metrics: Establishing normative values (2009) (20)
Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. (1991) (20)
Astrocytes and intracerebral immune responses (2004) (20)
To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. (2000) (20)
Impaired carotid baroreflex control of arterial blood pressure in multiple sclerosis. (2016) (20)
Diffusion tensor imaging the medial longitudinal fasciculus in INO: opportunities and challenges (2011) (19)
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS) (2010) (19)
Sympathomimetic-induced kaleidoscopic visual illusion associated with a reversible splenium lesion. (2006) (19)
Translational research in neurology and neuroscience 2010: multiple sclerosis. (2010) (18)
A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis Patients (2015) (18)
Visual Fixation Instability in Multiple Sclerosis Measured Using SLO-OCT. (2018) (17)
Multiple sclerosis. (2009) (17)
Part I. SARS-CoV-2 triggered ‘PANIC’1 attack in severe COVID-19 (2020) (17)
Reduced spontaneous sympathetic nerve activity in multiple sclerosis patients (2014) (17)
Capturing saccades in multiple sclerosis with a digitized test of rapid number naming (2017) (17)
Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis. (2015) (17)
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis. (2013) (16)
Impaired sweating responses to a passive whole body heat stress in individuals with multiple sclerosis. (2017) (16)
Neuro-ophthalmic manifestations of cerebellar disease. (2014) (16)
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. (2013) (16)
Multiple sclerosis-related white matter microstructural change alters the BOLD hemodynamic response (2016) (16)
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature (2016) (16)
Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis (2011) (16)
An update on neuro-ophthalmology of multiple sclerosis: the visual system as a model to study multiple sclerosis. (2014) (15)
Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis (2018) (15)
Is neuromyelitis optica distinct from multiple sclerosis?: something for "lumpers" and "splitters". (2007) (15)
Optical Coherence Tomography in Neurologic Diseases (2015) (15)
WEBINO and the Return of the King's Speech (2012) (15)
Symptomatic therapy in multiple sclerosis (2011) (15)
High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes (2017) (15)
Diagnosis and classification of optic neuritis (2022) (14)
Sexual Dysfunction in Neurologic Disease (2002) (14)
The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and The MS Council for Clinical Practice Guidelines (2002) (14)
Preserved canonicality of the BOLD hemodynamic response reflects healthy cognition: Insights into the healthy brain through the window of Multiple Sclerosis (2019) (14)
An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms (2004) (13)
Isolated mammillary body involvement on MRI in Wernicke's encephalopathy (2013) (13)
A surprisingly low prevalence of demonstrable stress urinary incontinence and pelvic organ prolapse in women with multiple sclerosis followed at a tertiary neurogenic bladder clinic. (2013) (13)
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology (2010) (13)
Objective characterization of the relative afferent pupillary defect in MS (2012) (12)
BREAK IN BINOCULAR FUSION DURING HEAD TURNING IN MS PATIENTS WITH INO (2008) (12)
Diagnosis and management of headache. (2001) (12)
Macular Ganglion Cell and Inner Plexiform Layer Thickness Is More Strongly Associated With Visual Function in Multiple Sclerosis Than Bruch Membrane Opening-Minimum Rim Width or Peripapillary Retinal Nerve Fiber Layer Thicknesses. (2019) (12)
Isolated relative afferent pupillary defect secondary to contralateral midbrain compression. (2004) (12)
Horizontal monocular saccadic failure: an unusual clinically isolated syndrome progressing to multiple sclerosis (2003) (12)
Calibrated imaging reveals altered grey matter metabolism related to white matter microstructure and symptom severity in multiple sclerosis (2017) (12)
Optic nerve head component responses of the multifocal electroretinogram in MS (2013) (12)
Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans (2018) (11)
Tetraethylammonium, a K+ channel blocker, inhibits interferon-γ-induced major histocompatibility class II antigen (Ia) expression and DNA synthesis in rat astrocytes (1991) (11)
Mitigating alemtuzumab-associated autoimmunity in MS (2020) (11)
Rehabilitation in Transverse Myelitis (2011) (11)
Multi-center, randomized, double-blinded assessment of dimethyl fumarate in extending the time to a first attack in radiologically isolated syndrome (RIS) (ARISE Trial) (P7.207) (2015) (11)
Microvascular blood flow velocities measured with a retinal function imager: inter-eye correlations in healthy controls and an exploration in multiple sclerosis (2018) (10)
Neurotherapeutic Strategies for Multiple Sclerosis. (2016) (10)
Characterizing retinal structure injury in African-Americans with multiple sclerosis. (2016) (10)
Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation (2013) (9)
Multiple sclerosis: Can retinal imaging accurately detect optic neuritis? (2010) (9)
Retinal architecture and mfERG (2014) (8)
Asynchrony in executive networks predicts cognitive slowing in multiple sclerosis. (2016) (8)
DNA plasmid vaccination for multiple sclerosis. (2007) (8)
Impaired sweating in multiple sclerosis leads to increased reliance on skin blood flow for heat dissipation (2010) (8)
Cognitive functioning in pediatric transverse myelitis (2013) (8)
Mitoxantrone-Associated Leukemia in Multiple Sclerosis: Case Studies (2008) (8)
Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis. (2016) (7)
Impaired Thermoregulatory Function during Dynamic Exercise in Multiple Sclerosis (2019) (7)
Autologous HSCT for advanced MS: is the glass half-empty or really half-full? (2008) (7)
Overdiagnosis of multiple sclerosis by magnetic resonance imaging (2006) (7)
Use of Imaging in Multiple Sclerosis (2010) (6)
New Ways of “Seeing” the Mechanistic Heterogeneity of Multiple Sclerosis Plaque Pathogenesis (2018) (6)
The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis (2022) (6)
Injury to a specific neural pathway detected by ultra-high-field MRI (2014) (6)
Humoral immune responses after rabies infection. (2007) (6)
Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon (2018) (5)
Diagnosis and management of multiple sclerosis: case studies. (2006) (5)
Neurogenic sexual dysfunction in men and women (2001) (5)
Academy of transverse myelitis : Report of the Therapeutics and Technology Evidence-based guideline : Clinical evaluation and treatment of December 16 (2011) (5)
Multiple sclerosis and magnetic resonance imaging: advancement in linking the pictures with the progression. (2001) (5)
From injection therapies to natalizumab: views on the treatment of multiple sclerosis (2012) (5)
Pearls: multiple sclerosis. (2010) (5)
Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy (2021) (5)
Retinal Oximetry-Derived Biomarkers of Metabolic Dysfunction in MS (P5.307) (2015) (5)
Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? (2020) (4)
Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms (2006) (4)
Immune-Mediated Myelopathies (2015) (4)
High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes. (2007) (4)
Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus (2016) (4)
Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects (2007) (4)
Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients (2007) (4)
Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes (2022) (4)
Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis. (2009) (4)
The menagerie of neurology: Animal signs and the refinement of clinical acumen (2014) (4)
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1 (2020) (3)
Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort (2022) (3)
W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th century. (2007) (3)
Clinical/Scientific Notes (2011) (3)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] (2007) (3)
A young man with numbness in arms and legs (2018) (2)
Optical coherence tomography in neurological diseases (2015) (2)
Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis (2008) (2)
A young man in “double-trouble”: Hallucinations and cranial nerve palsies (2018) (2)
Multicenter Retrospective Study Of Extended Dosing Of Natalizumab In Multiple Sclerosis: A Strategy For Mitigating Risk Of Progressive Multifocal Leukoencephalopathy While Maintaining Efficacy? (P2.251) (2014) (2)
Introduction to optical coherence tomography in neurological diseases (2015) (2)
Relevance of CD34+ cells as a reservoir for JC virus in patients with multiple sclerosis--reply. (2014) (2)
Encephalitis and Myelitis in a Young Woman (2021) (2)
PATIENTS WITH MULTIPLE SCLEROSIS AND NEUROVESICAL DYSFUNCTION ARE AT EXTREMELY LOW RISK FOR UPPER TRACT DETERIORATION (2008) (2)
Basic principles of optical coherence tomography (2015) (2)
The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard ‘Dick’ T. Johnson (2017) (2)
BRAIN LETTER TO THE EDITOR Reply: Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography (2011) (2)
More on Multiple Sclerosis and Neuromyelitis Optica. Authors' reply (2007) (2)
Meta-analysis of optical coherence tomography in multiple sclerosis (2015) (2)
Pearls & Oy-sters: “Not multiple sclerosis” and the changing face of HTLV-1 (2009) (2)
MMPI-2 interpretation and multiple sclerosis (1998) (1)
Optimal Inter-Eye Difference Thresholds in Retinal Nerve Fiber Layer and Ganglion Cell Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis: An International Collaborative Study (P2.160) (2018) (1)
New Frontiers of MR-Based Techniques in Multiple Sclerosis (2004) (1)
DEFINING SUCCESS IN MULTIPLE SCLEROSIS: TREATMENT FAILURES AND NONRESPONDERS * (2008) (1)
Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease☆ (2021) (1)
B cells from relapsing remitting multiple sclerosis patients modulate T cell behavior in a neuroantigen-specific manner (HUM1P.322) (2014) (1)
A Large Tertiary Care Multiple Sclerosis Center Experience with Oral Fingolimod (FTY 720) (P04.146) (2012) (1)
Decreases in Core Temperature and Sweating Onset During Whole‐body Heating in Individuals with Multiple Sclerosis Following Administration of 4‐aminopyridine (2016) (1)
Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis? (2018) (1)
Comparison of Cirrus and Spectralis Optical Coherence Tomography: Factors Associated With Differences in Retinal Nerve Fiber Thickness Measurement (P5.312) (2015) (1)
Visual Pathway Structure and Function, Optic Neuritis and Fatigue in Multiple Sclerosis. (S39.008) (2014) (1)
Safety and Efficacy of Extended Dose Natalizumab in Multiple Sclerosis: An Ongoing Multicenter Study. (P3.267) (2015) (1)
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2 (2020) (1)
Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2 (2021) (1)
Interferon beta and long-term disability in multiple sclerosis--reply. (2013) (1)
Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient (2019) (1)
Characteristics of morphologic macular abnormalities in neuroimmunology practice (2019) (1)
Vestibular testing and multiple sclerosis (2010) (1)
Cerebellar syndrome in a man treated with natalizumab (2019) (1)
A Novel Diagnostic Tool for Myasthenia Gravis : Ocular Vestibular Evoked Myogenic Potentials (2015) (1)
INDUCTION-UP-REGULATION OF ICAM-1 IN CULTURED HUMAN-BRAIN ASTROCYTES (1988) (1)
More on multiple sclerosis and neuromyelitis optica: In reply [5] (2007) (1)
Erratum: Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (Neurology (2007) 68, (977-984)) (2007) (1)
In-Vivo Assessment of Retinal Neuronal Layers in Multiple Sclerosis with Manual and Automated Optical Coherence Tomography Segmentation Techniques (S10.003) (2012) (1)
Core temperature is not elevated at rest in people with relapsing-remitting multiple sclerosis. (2019) (1)
Multiple sclerosis. (2004) (1)
Genetic analysis of the exon 1 position 49 CD152 dimorphism in multiple sclerosis (2007) (1)
Acute optic neuritis: a clinical paradigm for evaluation of neuroprotective and restorative strategies? (2015) (1)
Food for Thought: A Serving of Food-Inspired Eponyms in Neurologic Practice (P1.296) (2014) (0)
Ocular Motor Biomarkers of Progressive Cerebral Dysfunction in Multiple Sclerosis (P5.222) (2015) (0)
Clinical and Ocular Imaging Characteristics of Eyes With Visual Loss Over Time in Multiple Sclerosis (2009) (0)
Autoreactive Regulatory CD8+ T Cells in Multiple Sclerosis (2010) (0)
The Effects of Horizontal Head Position (Yaw axis) and Step Velocity on the Vestibulo‐Ocular Reflex (2002) (0)
The potential involvement of plasmablast antibodies in clinically isolated syndrome and multiple sclerosis (HUM3P.268) (2015) (0)
Comparison of antibody gene mutation patterns in first attack optic neuritis and transverse myelitis leading to Multiple Sclerosis (47.18) (2011) (0)
Interferon therapy of multiple sclerosis Edited by Anthony Reder New York, Marcel Dekker, 1997 5150 pp, illustrated, $195.00 (1998) (0)
Retinal Atrophy Measured by Optical Coherence Tomography Predicts Disability Progression in Multiple Sclerosis (S45.007) (2016) (0)
Optical Coherence Tomography in Parkinson’s Disease: Retinal Structural Injury and Insights into Disease Pathology (P1.048) (2014) (0)
Visual Function and Optical Coherence Tomography in Pediatric Demyelinating Diseases (P01.158) (2012) (0)
Deriving Clinically Useful Visual Evoked Potential Measurements from 120 Sector Multi-Focal Visual Evoked Potential Sequences (P07.259) (2012) (0)
Retinal Structural Injury Is Worse in African-Americans Than Caucasians with Multiple Sclerosis (P2.261) (2014) (0)
Do Particular Antibody Genes Drive Development of MS? (S20.004) (2012) (0)
Retinal Structure Injury and CSF Humoral Response in Multiple Sclerosis (P5.240) (2015) (0)
NAIL-ing the Diagnosis: Real Neurologists Pay Attention to the Nails (P1.030) (2014) (0)
Arterial baroreflex control of sympathetic nerve activity in multiple sclerosis (2009) (0)
Application of diagnostic criteria for optic neuritis – Authors' reply (2023) (0)
precoolingduring exercise after lower vs. whole body Metabolic, thermoregulatory, and perceptual (2015) (0)
Norepinephrine antagonizes gamma interferon induced class II MHC on cultured brain astrocytes (1987) (0)
Asymmetry in Retinal Properties of Image ‘Delivery’ and Perceptual Processing in the Visual Cortices in MS: The Pulfrich Phenomenon (2018) (0)
Neurology of bladder, bowel, and sexual dysfunction. Blue books of practical neurology, vol 23 (2000) (0)
MOG Antibody–Associated Disease and Thymic Hyperplasia (2022) (0)
Do particular antibody genes recognize gray matter cellular targets? (HUM2P.338) (2014) (0)
Blunted Arterial Blood Pressure Responses to Whole‐Body Cold Stress in Individuals with Multiple Sclerosis (2016) (0)
Optical coherence tomography and electrophysiology of the optic nerve head (2015) (0)
Addressing the challenges in risk assessment and risk management in multiple sclerosis (2012) (0)
Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery (2022) (0)
Unique antibody gene signature in Multiple Sclerosis (2009) (0)
A New Method for Diagnosing Multiple Sclerosis: Use of 454 Sequencing To Identify Somatic Hypermutation Frequency in B Cells from Multiple Sclerosis Patients (P02.103) (2012) (0)
An Open Labeled Observational Study of Rituximab and Plasma Exchange (PLEX) in Progressive Multiple Sclerosis (MS) (P3.264) (2015) (0)
Vision as a Structural and Functional Correlate to Fatigue and Disability in Multiple Sclerosis (2013) (0)
Optical Coherence Tomography in Parkinson’s Disease: A Potential in-vivo Retinal α-Synuclein Biomarker in Parkinson’s Disease (2015) (0)
In memoriam: The legacies of John F. Kurtzke and Richard T. Johnson (2016) (0)
Immediate induction of enhanced CD8 suppressive function following glatiramer acetate therapy in multiple sclerosis (164.20) (2011) (0)
Interferon Nab Testing for MS: Case Studies (2007) (0)
Optical coherence tomography and visual outcomes in acute optic neuritis (2015) (0)
1291: Impact of a Closed Bladder Outlet on Neurogenic Detrusor Overactivity (2006) (0)
Mechanisms and Modulators of Temperature Regulation Thermoregulation in multiple sclerosis (2010) (0)
Chapter 6. Use of Imaging in Multiple Sclerosis (2008) (0)
The Optic Nerve Head Component: A Novel Eletrophysiologic Marker of Optic Neuropathy in Multiple Sclerosis and Neuromyelitis Optica (S48.001) (2012) (0)
CORRECTION (2008) (0)
Additionally, plasmablasts from TM patients show evidence for positive selection with increased somatic hypermutation accumulation in VH4 þ B cells and receptor editing that is not observed in ON patients. These characteristics unique to TM patients (2013) (0)
Use of IL- 2 for Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy (P4.035) (2015) (0)
Evaluating Retinal Abnormalities in Patients With Multiple Sclerosis—Reply (2010) (0)
1878 A SURPRISINGLY LOW PREVALENCE OF DEMONSTRABLE STRESS URINARY INCONTINENCE IN WOMEN WITH MULTIPLE SCLEROSIS FOLLOWED AT A TERTIARY NEUROUROLOGY CLINIC (2012) (0)
Multiple Sclerosis Impairs Sweating but not Skin Blood Flow during a Passive Whole-Body Heat Stress: 138 May 31 10 (2017) (0)
Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize ‘one’ while treating the ‘other’ (2013) (0)
The Optic Nerve Head Component of the Multifocal Electroretinogram: A Novel Metric for Dissecting Pathophysiologic Mechanisms in MS (S10.001) (2012) (0)
An in vivo assessment of the brain in Alzheimer's disease. (1986) (0)
The auto-reactive profile of B cells from early MS patients (2016) (0)
A Tour through the Zoo of Neurology: Animal Eponyms and the Refinement of Clinical Acumen (P05.263) (2013) (0)
Retinal inflammation in multiple sclerosis revealed by optical coherence tomography and ophthalmoscopy (2015) (0)
Disease exacerbation in multiple sclerosis patients is characterized by loss of terminally differentiated neuroantigen-specific CD8+ Tregs (P3115) (2013) (0)
Encephalitis and Myelitis in a Young Woman Overlap Syndrome, Thyroiditis, and Occult Tumor From the National Multiple Sclerosis Society Case Conference Proceedings (0)
Memory B cells from relapsing remitting multiple sclerosis patients elicit functional responses by CD4+ T cells in response to neuro-antigens (135.24) (2010) (0)
Monitoring Treatment in Multiple Sclerosis (2016) (0)
Application of a Novel Diagnostic Test to Patients with Demyelinating Disease: The Accuracy of MSPrecise ™ (P03.242) (2013) (0)
The Pulfrich Phenomenon: An Objective Signature-Biomarker of MS Pathophysiology (P1.327) (2015) (0)
Immunobiology of antigen presenting cells during relapse vs. remission in multiple sclerosis (2016) (0)
What you see is what you get (2007) (0)
Differing Distribution of Men and Women in Transient Global and Transient Ischemic Attacks: Does Exogenous Estrogen Play a Role? (1988) (0)
Glucocerebrosidase Mutations and Risk (2017) (0)
Temperature Induced Decrements of Ocular Motor Function in Multiple Sclerosis Patients: 2049 (2006) (0)
Assessment of Multiple Sclerosis Patients with a Known History of Unilateral Optic Neuritis Shows Optic Nerve Head Component Loss in the Fellow Unaffected Eye (S58.004) (2012) (0)
Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder (2022) (0)
Precision Terminology (2022) (0)
An Analysis Of Novel Antibody Repertoires In Patients With Multiple Sclerosis: Do Particular Antibody Genes Recognize Gray Matter Cellular Targets? (P6.157) (2014) (0)
Antigen reactivity of B cells from patients at risk to develop Multiple Sclerosis demonstrates a specific somatic mutation pattern. (159.28) (2012) (0)
Improvements in sweat function during whole‐body heating in multiple sclerosis patients following administration of 4‐aminopyridine (2011) (0)
Clinical and Radiological Disease Activity Is Associated with Accelerated Rates of Retinal Ganglion Cell Layer Degeneration in Multiple Sclerosis (S10.002) (2012) (0)
Optical coherence tomography in a multi-center setting: quality control issues (2015) (0)
Retinal Thickness and Visual Disability in Patients with Multiple Sclerosis and Disease-Free Controls with Myopia (S48.008) (2016) (0)
Structural and Functional Measures of the Optic Nerve, Determining the Best Correlate for Visual Acuity (P01.159) (2012) (0)
Prion Peptide P3: A Normal Component of Skin? (1987) (0)
What Effect Does Pregnancy Have on MS Relapse Rate (2004) (0)
In reply [4] (2006) (0)
Optical coherence tomography in acute optic neuritis (2015) (0)
An Overlap in the Humoral Immune Response by NMO and MS Patients That Is Distinct from Patients with Other Neurological Diseases (P02.067) (2012) (0)
Contribution of memory and naïve B cells to myelin specific T cell function in relapsing remitting multiple sclerosis (99.8) (2009) (0)
Retinal neuronal and axonal loss over time as markers of disease progression and activity in Multiple Sclerosis: A pilot study (P5.223) (2015) (0)
The Downstream Implications of Somatic Hypermutation in Multiple Sclerosis: What Are the Cellular Targets of Antibodies Produced by MS Patient CSF Derived B Cells? (P03.223) (2013) (0)
estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived (2011) (0)
Relation of Ganglion Cell Layer Thinning to Axonal Loss, Visual Function, and Quality of Life in Multiple Sclerosis (2011) (0)
Unique antibody gene signature in Multiple Sclerosis (49.25) (2009) (0)
Hearing abnormalities in multiple sclerosis: clinical semiology and pathophysiologic mechanisms (2022) (0)
Reply to Letters to the Editor (2018) (0)
Re: Urinary Retention: Benefit of Gradual Bladder DecompressiondMyth or Truth? A Randomized Controlled Trial (2015) (0)
Optical coherence tomography angiography measurements in multiple sclerosis: a systematic review and meta-analysis (2023) (0)
Neuroradiology: applications in neurology and neurosurgery (1988) (0)
Good Vibrations: A Novel Method of Damping Acquired Pendular Nystagmus with Vibration (S19.001) (2014) (0)
Preserved Tolerance to Lower‐Body Negative Pressure during Heat Stress in Individuals with Multiple Sclerosis (2017) (0)
The Effect of Natalizumab Therapy On Immune Surveillance of the Central Nervous System in Multiple Sclerosis Patients (2006) (0)
Neuromyelitis Optica: Immunopathogenesis, Clinical Manifestations, and Treatments (2017) (0)
URODYNAMIC FINDINGS AND LOWER URINARY TRACT SYMPTOMS IN MULTIPLE SCLEROSIS PATIENTS WITH INTERNUCLEAR OPHTHALMOPLEGIA (1999) (0)
Imaging for Neurological Disease: Current Status and New Developments (1988) (0)
F.12. Immune Regulatory Role for CNS-specific, Autoreactive CD8 T Cells in Multiple Sclerosis (2008) (0)
In Memoriam: John F. Kurtzke, MD (1926-2015): A Founding Father of Neuroepidemiology and Pioneer of Modern Clinical Trial Design. (2016) (0)
Longitudinal assessment of rates of brain and retinal atrophy in African American versus Caucasian American patients with Multiple Sclerosis (S47.003) (2018) (0)
Longitudinal Study of Retinal Ganglion Cell Layer Thickness by OCT in Multiple Sclerosis (S48.003) (2012) (0)
Comparison of Serum and Various Types of Plasma from Multiple Sclerosis Patients for Biomarker Studies (P02.093) (2012) (0)
Microcystic Macular Edema in Neuromyelitis Optica Is Associated with Visual Disability and Retinal Axonal and Neuronal Loss (IN4-1.009) (2013) (0)
Home treatment of mild/moderate COVID-19: To prevent severe disease: IMAGINE? (2021) (0)
Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)? (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Elliot Mark Frohman?

Elliot Mark Frohman is affiliated with the following schools:

Elliot Mark Frohman's Academic­Influence.com Rankings

Why Is Elliot Mark Frohman Influential?

Elliot Mark Frohman's Published Works

Published Works

What Schools Are Affiliated With Elliot Mark Frohman?

Elliot Mark Frohman's AcademicInfluence.com Rankings